Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of joining the trial.
• People with a confirmed diagnosis of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, with a high-grade serous or predominantly serous/endometroid type — meaning the cancer came back or kept growing within 6 months of the last platinum-based chemotherapy treatment.
• People who have received no more than 2 prior treatment regimens for their platinum-resistant disease. Those whose cancer tests positive for high folate receptor alpha (FR alpha), as determined by an FDA-approved test, must have previously received a treatment called mirvetuximab soravtansine (MIRV), unless there is a documented medical reason they could not receive it (confirm with trial site).
• People who have at least one measurable area of cancer visible on a CT or MRI scan, meeting specific size requirements under standard measurement guidelines.
• People with a good general health and activity level, rated 0 or 1 on a standard performance scale (meaning fully active or able to carry out light work).
• People with known cancer spread to the brain, provided the brain has already been treated, symptoms have been stable for at least 4 weeks, and no steroids or anti-seizure medications are currently needed.
• People whose blood and organ function test results fall within acceptable ranges, including blood cell counts, kidney function, liver function, and blood clotting measures — with albumin levels checked at two time points (confirm with trial site).
• People who have had limited radiation therapy for pain relief in the 5 weeks before starting the trial.
• Women who could become pregnant must have a negative pregnancy test before joining.
• People who are willing and able to use adequate contraception throughout the trial and for at least 3 months after the last dose, and to avoid tissue donation during that time.
• People whose side effects from any previous cancer treatment have mostly resolved before starting the trial (with exceptions for hair loss and certain nerve-related symptoms).

Who may not be able to join:

• People diagnosed with another active cancer (other than the ovarian/fallopian/peritoneal cancer being studied) within the past 2 years — though certain treated skin cancers or pre-cancerous conditions of the breast or cervix may be exceptions (confirm with trial site).
• People with a history of certain lung conditions (such as pulmonary fibrosis, sarcoidosis, or hypersensitivity pneumonia), serious heart conditions (such as a recent heart attack, unstable angina, uncontrolled irregular heartbeat, or severe heart failure), or a need for a fluid-draining procedure from the abdomen within 4 weeks before screening.
• People whose cancer never responded at all to their first platinum-based chemotherapy (known as primary refractory disease).
• People who have received radiation to target lesions, chemotherapy, or other systemic cancer treatments (including anti-angiogenic drugs like bevacizumab) within 4 weeks before starting the trial.
• People who have needed a procedure to drain fluid from the abdomen within 2 weeks before signing the consent form.
• People with any other medical, mental health, or personal circumstances that the investigator believes would make participation unsafe or unsuitable.
• People who have had major surgery (other than a diagnostic procedure) within 4 weeks before the first day of treatment.
• People with a prior or current history of bleeding inside the eye (hyphema) or glaucoma.
• People with a history of sickle cell disease or a certain inherited type of blood disorder affecting red blood cells.
• People whose heart rhythm measurement (QTc interval) on an ECG exceeds the acceptable limit for their sex (confirm with trial site).
• People who are unwilling or unable to follow study procedures, or who plan to take a vacation of more than 7 consecutive days during the trial.
• People who are a close family member of the investigator, study staff, or trial sponsor.
• People who have received chemotherapy within 3 weeks, or other cancer treatments within 4 weeks (or 6 weeks for certain specific drugs), before the first dose of the trial drug misetionamide.
• People who have taken part in another experimental treatment trial within 4 weeks before the first dose of misetionamide.

Important: Always verify eligibility with the trial site directly before applying.